SubHero Banner
Text

Afinitor Disperz® (everolimus) – Expanded indication

April 10, 2018 - The FDA announced the approval of Novartis’ Afinitor Disperz (everolimus) tablets for oral suspension, for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.

Download PDF